about
Low-dose irradiation promotes tissue revascularization through VEGF release from mast cells and MMP-9-mediated progenitor cell mobilizationModel-specific selection of molecular targets for heart failure gene therapyA visible, targeted high-efficiency gene delivery and transfection strategyAngiogenic therapy for coronary artery and peripheral arterial disease.Dose-dependent neovascularization-promoting effect of adenovirus vector CI-1023 in a rat hindlimb ischaemic model.Alcohol-induced hypertension: Mechanism and prevention.Low energy shock wave therapy induces angiogenesis in acute hind-limb ischemia via VEGF receptor 2 phosphorylation.Orchestration of angiogenesis and arteriovenous contribution by angiopoietins and vascular endothelial growth factor (VEGF).Bioreducible polymers for therapeutic gene deliveryMolecular imaging of the kinetics of vascular endothelial growth factor gene expression in ischemic myocardiumCardiac gene therapyEngineered calmodulins reveal the unexpected eminence of Ca2+ channel inactivation in controlling heart excitation.Molecular imaging of RNA interference therapy targeting PHD2 for treatment of myocardial ischemia.In vivo gene delivery of XIAP protects against myocardial apoptosis and infarction following ischemia/reperfusion in conscious rabbits.Heart failure in 10 years time: focus on pharmacological treatment.Angiogenic functions of voltage-gated Na+ Channels in human endothelial cells: modulation of vascular endothelial growth factor (VEGF) signaling.Targeting calcium cycling proteins in heart failure through gene transfer.Relative roles of direct regeneration versus paracrine effects of human cardiosphere-derived cells transplanted into infarcted mice.Outcomes of middle cardiac vein arterialization via internal mammary/thoracic artery anastomosis.Emerging therapeutic targets in chronic heart failure: part II.Targeting signaling pathways in heart failure by gene transfer.Elevation of vascular endothelial growth factor production and its effect on revascularization and function of graft islets in diabetic rats.Angiogenesis: a curse or cure?Cell transplantation and genetic engineering: new approaches to cardiac pathology.Myoblast-mediated gene transfer for therapeutic angiogenesis and arteriogenesis.Manipulating angiogenesis in medicine.Hypoxia induces angiogenic factors in brain microvascular endothelial cells.Cardiovascular gene therapy: current status and therapeutic potential.Chronic ethanol ingestion induces aortic inflammation/oxidative endothelial injury and hypertension in rats.Positron emission tomography reporter gene imaging in the myocardium: for monitoring of angiogenic gene therapy in ischemic heart disease.Stem cells as biological heart pacemakers.Endothelial progenitor cells and their potential clinical applications in peripheral arterial disease.Lymphangiogenic gene therapy with minimal blood vascular side effectsIschaemia is linked to inflammation and induction of angiogenesis in pancreatic islets.From gene therapy and stem cells to clinical electrophysiology.Isolation and expansion of resident cardiac progenitor cells.Gene therapy in the treatment of heart failure.Thymosin beta-4 is essential for coronary vessel development and promotes neovascularization via adult epicardium.Biological approaches to ischemic tissue repair: gene- and cell-based strategies.Myocardial repair: from salvage to tissue reconstruction.
P2860
Q24646424-F81919B7-9CF4-4590-832D-7D4B1524B290Q26823061-78AF7DA0-EFF5-45F3-9289-6280BFDBA7E0Q30475161-E8EC5418-BDE3-4ED0-8E78-A56C8E9AC111Q30783593-D61607E7-91E4-423A-BB4C-4B00843AA5BAQ31114069-E4A1F6CF-377A-4760-A6A3-23072B1893B3Q33686885-53069FC3-D229-4FB9-A698-0CFEA5BC02B8Q34004811-938DA422-3C10-48E3-91B6-516F40822BF2Q34032032-6D20D938-8A76-4452-BC2B-DC73949C00ADQ34079568-AED42A22-55A8-4384-B17E-EF72715EE435Q34134323-8C0A0E08-ADFF-47D3-A250-9E044B55E99AQ34409721-BF6C4CC0-0AB9-4E81-8641-6F5CDDACC38EQ34431265-98C48C34-1374-4197-B412-8E0841A6B5CDQ34601238-910D4695-2A3A-4D63-8447-1AA6241685D9Q34717828-FC3E52DC-1F8E-4DB5-AFF0-E94E280E3002Q34817094-274BE300-EB3D-4562-8EE9-0BDD4742072EQ34947687-31467A28-26B1-4F4F-86E6-41237D49A06DQ35037546-13707FBA-C02D-4B98-9778-420C4B4DABCEQ35050037-ED024585-F210-446C-A5E4-93CB74C952D9Q35053796-88E94260-FA88-4A71-8670-19FBE8788C1AQ35056026-F1F8065B-D30D-4752-923F-660C05990DC7Q35095401-DA411C91-16A9-4650-8D22-95269EAFE42EQ35397286-DEE345A4-1F7A-4BC8-BE64-44093767A977Q35521647-50FA039C-51AE-4224-B752-4ED8134EA0A2Q35547250-33589D04-1342-4442-BB52-A4EDA97DE238Q35554334-9D305864-FD5A-4EAB-B609-13BC13E086E2Q35743851-C43953B5-8F9F-4C12-85E1-5DCF0C424216Q35754099-A9301930-BCC5-43A2-A4BA-B506C1EE66A3Q35995220-92C6CD38-1512-4534-B014-244CC921BE06Q36295836-450033B6-2EBA-4016-9B12-12480025B750Q36321294-78846AE0-5530-4DB1-9C2D-5ABE83BA453AQ36327036-C3B7323D-9D4E-407B-A13A-5F75486E90BAQ36367251-B39EF4E8-99AC-411E-8CE7-87B3A63D711CQ36371262-5ABCB029-4F67-4F69-9330-84532B401432Q36458495-E4A6F8B6-7E16-44FD-BAFC-C2359C06C44FQ36596746-AD993A05-5707-43DA-B01F-7F5176ABDABDQ36691627-C0DB2FF3-B0A9-4145-95D9-7C3D474CA50AQ36786243-0ECB0AF6-A827-4F2D-8B6F-BFC3A7301E15Q36818229-E246382F-895C-44B4-83E5-F6E3ED4083C2Q37176436-8581445F-0F91-4C2D-B584-E22743D32FB5Q37176440-1FA59390-0BE2-4F39-90F6-E10E4BAF0AA5
P2860
description
2002 nî lūn-bûn
@nan
2002 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Myocardial gene therapy.
@ast
Myocardial gene therapy.
@en
Myocardial gene therapy.
@nl
type
label
Myocardial gene therapy.
@ast
Myocardial gene therapy.
@en
Myocardial gene therapy.
@nl
prefLabel
Myocardial gene therapy.
@ast
Myocardial gene therapy.
@en
Myocardial gene therapy.
@nl
P356
P1433
P1476
Myocardial gene therapy.
@en
P2093
Jeffrey M Isner
P2888
P304
P356
10.1038/415234A
P407
P577
2002-01-01T00:00:00Z
P5875
P6179
1015714386